![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, March 21, 2017 8:42:47 AM
"The Company has significant operating cash flow deficiencies. Additionally, the Company will need significant funding for future operations and the expenditures that will be required to conduct the clinical and regulatory work to develop the Company’s product candidates, commercially launch any products that may be approved by applicable regulatory authorities, market and sell products and otherwise support the Company's intended business activities. Management’s plans include attempting to secure additional required funding through equity or debt financings, sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions, in order to satisfy existing obligations, liabilities and future working capital needs, to build working capital reserves, to fund the Company’s research and development projects and to support the operations of USC. There is no assurance that the Company will be successful in obtaining the necessary funding to meet its business objectives."
https://www.sec.gov/Archives/edgar/data/887247/000138713116007979/admp-10q_093016.htm
When in doubt, call IR. Don't attack people here for posting true, useful information before doing your own DD.
Recent ADMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:50:07 PM
- Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus • GlobeNewswire Inc. • 09/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 09:20:33 PM
- Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/21/2023 01:15:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:38:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 08/10/2023 08:03:30 PM
- Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/04/2023 05:43:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:59:45 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/03/2023 08:55:39 PM
- Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/02/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2023 04:15:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 09:01:12 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/28/2023 08:58:05 PM
- Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert • GlobeNewswire Inc. • 07/28/2023 12:30:00 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 07/27/2023 10:08:01 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/27/2023 01:17:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:15:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/13/2023 08:37:24 PM
- Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/26/2023 11:30:00 AM
- Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention • GlobeNewswire Inc. • 06/22/2023 11:30:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM